Anavex Life Sciences Corp (AVXL)

[sokol]

Power:

Bio posted detailed discussions about this today that you should read. Briefly, it is believed, from the genome work do so far, that AVXL 2-73 may get the same response from patients in the PDD trial as we have seen so far in the AD trial.

All three clinical trials (AD, PDD and Rett) will be looking at the same genetic groups as identified in the AD Phase 2a trial. If we can show that patients included in the 80% genetic success group show positive results for AVXL 2-73 whereas the 20% genetic group does not respond to the drug, we can attribute the drug’s success to the gene matching identified in Anavex’s genome work completed and announced at AIC 2018.

In other words, it is expected that our drug, if successful, should get a positive response from the 80% of patients that have genes matching the 80% of the patient population and those that do not get the same result, 20% of the population, should be in the genetically identified failure group. if we get the same response in the PDD trial as has been identified in the AD trial this far, it should indicate proof of efficacy to be further confirmed later with the completion of the AD Phase 2/3 trial (48 months), which will be longer than the PDD trial in Spain (14 months).

It is getting late for me so I hope I have accurately expressed what we will be looking for in any or all of the 3 clinical trials. We can discuss this more later.